• Explore /
  • Poster
  • / Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.

Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.

Abstract Poster

Authors

null

Sofie Kirial Mørk

National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark, Herlev, Denmark

Sofie Kirial Mørk , Signe Koggersbøl Skadborg , Benedetta Albieri , Arianna Draghi , Marie Christine Wulff Westergaard , Joachim Stoltenborg Granhøj , Mohammad Kadivar , Nikolas Thuesen , Ida Svahn Rasmussen , Christina Westmose Yde , Nis Nørgaard , Torben Lorentzen , Nadia Viborg Petersen , Anders Jespersen , Dennis Christensen , Jens Vindahl Kringelum , Marco Donia , Sine Reker Hadrup , Inge Marie Svane

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03715985

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9551)

DOI

10.1200/JCO.2023.41.16_suppl.9551

Abstract #

9551

Poster Bd #

314

Abstract Disclosures

Similar Posters

First Author: Mark Yarchoan

Poster

2021 ASCO Annual Meeting

A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.

A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.

First Author: Aaron Miller

First Author: Craig L. Slingluff Jr.

First Author: Aung Naing